LCLAT1 and melanoma: At the protein level, proteomics of melanoma responses to immunotherapy have revealed mitochondrial-dependent signatures that correlate with treatment efficacy [68], while specific biomarkers like lysocardiolipin acyltransferase 1 (LCLAT1) show prognostic potential in hepatocellular carcinoma by reflecting tumor immunity status and mitochondrial function [69].